PET Imaging of Inflammation and Lipid Lowering Study
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging has been used
as an early marker of drug efficacy in numerous clinical cardiovascular drug trials, as a
glucose analog, its signal in the vasculature lacks inflammatory cell-specificity. Moreover,
high background 18F-FDG signals from the myocardium often preclude coronary artery imaging,
despite attempts to suppress myocardial tracer uptake by dietary manipulation. These
limitations of 18F-FDG for measuring changes in vascular inflammation arising from drug
intervention highlight important unmet needs, which might be overcome by using a somatostatin
receptor subtype-2 (SST2) PET tracer.
Phase:
N/A
Details
Lead Sponsor:
University of Cambridge
Collaborators:
Cambridge University Hospitals NHS Foundation Trust Wellcome Trust